IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study

Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy

(2022) Jicheng Lv et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial

(2022) et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

(2022) Jonathan Barratt et al.   KIDNEY INTERNATIONAL

A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy

(2021) David C. Wheeler et al.   KIDNEY INTERNATIONAL

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

(2021) Brad H. Rovin et al.   KIDNEY INTERNATIONAL

Dapagliflozin in Patients with Chronic Kidney Disease

(2020) Hiddo J.L. Heerspink et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study

(2019) Simon Jarrick et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

(2019) Hiddo J L Heerspink et al.   LANCET

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

(2019) Hiddo J L Heerspink et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Epidemiology of IgA Nephropathy: A Global Perspective

(2018) Francesco Paolo Schena et al.   SEMINARS IN NEPHROLOGY

DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS

(2018) Howard Trachtman et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease

(2016) Radko Komers et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

IgA nephropathy

(2016) Kar Neng Lai et al.   Nature Reviews Disease Primers

Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study

(2015) V. Tesar et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Intensive Supportive Care plus Immunosuppression in IgA Nephropathy

(2015) Thomas Rauen et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy

(2014) D. de Zeeuw et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Endothelin and endothelin antagonists in chronic kidney disease

(2014) Donald E Kohan et al.   KIDNEY INTERNATIONAL

A New Equation to Estimate Glomerular Filtration Rate

(2013) Andrew S. Levey et al.   ANNALS OF INTERNAL MEDICINE

Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease

(2013) Sean J. Barbour et al.   KIDNEY INTERNATIONAL

Selective Endothelin-A Receptor Antagonism Reduces Proteinuria, Blood Pressure, and Arterial Stiffness in Chronic Proteinuric Kidney Disease

(2011) Neeraj Dhaun et al.   HYPERTENSION

Predicting the Risk for Dialysis or Death in IgA Nephropathy

(2011) F. Berthoux et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

The incidence of primary glomerulonephritis worldwide: a systematic review of the literature

(2010) A. McGrogan et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION